Welcome

Celebrating Over 75 Years Of Service

The American Academy of Otolaryngic Allergy (AAOA) represents over 2,700 Board-certified otolaryngologists and health care providers. Otolaryngology, frequently referred to as Ear, Nose, and Throat (ENT), uniquely combines medical and surgical expertise to care for patients with a variety of conditions affecting the ears, nose, and throat, as well as commonly related conditions. AAOA members devote part of their practice to the diagnosis and treatment of allergic disease. The AAOA actively supports its membership through education, research, and advocacy in the care of allergic patients.

"Dedicated to enhancing knowledge and skill in the care of the allergic patient."

ADVOCACY UPDATES

Changes in MACRA

Macra 101 Image

Before the close of 2017, all physicians must take action to avoid the 4 percent cut that will be assessed in 2019 for not participating in the new Quality Payment Program (QPP) authorized by the Medicare Access and CHIP Reauthorization Act (MACRA).  Read More

CMS Announces Changes in MACRA Implementation Timeline. The Centers for Medicare and Medicaid Services (CMS) announced major changes to the implementation of the Medicare Access and CHIP Re-authorization (MACRA).
Read More

Upcoming Dates

07/31/19: Membership Application Deadline to be voted in at the 2019 Annual Meeting and to be eligible for AAOA Member Rate (FREE) for the 2019 Annual Meeting
Learn more

12/01/19: Research Grant Cycle
Learn more

04/01/20: Fellow Exam Application Deadline
Learn more

06/01/20: Research Grant Cycle
Learn more

06/01/20: Call For Scientific Abstracts Deadline
Watch Your Email

06/7/20: Membership Application Deadline to be eligible for AAOA Member rate for the 2020 Basic Course

EDUCATION

New Orleans: Should I Stay or Should I Go?

Much like the Clash song lyrics, many of you will flip through this AAOA Today issue trying to assess whether it is worth the cost to get on a plane to participate in the AAOA’s Annual Meeting. We recognize you have lots of CME options, some are even competing with our meeting in New Orleans. Read More

IFAR

IFAR Impact Factor: 2.454

aaoaf-ifar

Now Available

Changes in Managing Practices

Mission

Working together with AAOA staff, volunteer leadership and members will enable us to have a positive impact on our members’ practices.

Read More

Live and Online CME

2019 AAOA Annual Meeting
September 13-15 | New Orleans, LA
Learn More and Register

2019 Advanced Course in Allergy & Immunology
December 12-14 | Austin, TX
Learn More and Register

2020 Basic Course in Allergy & Immunology
July 9-11 | Orlando, FL
Save the Date

AAOA Clinical Insights
Learn More and Register

PATIENT CORNER

History of Allergy Treatment

The history of modern allergy treatment dates back to the early decades of the twentieth century with the demonstration of decreased response to grass pollens following conjunctival challenge done by Noon and Freeman.

Read More

News and Updates

Practice Management

Strategies & Tactics to Improve Efficiencies for Better Patient Care In response to member feedback, we…

read more

ReCAP — Review Of Core Allergy Principles

The AAOA Education Committee is pleased to announce that, in addition to updating the format and educational venue…

read more

NEW! Windy City Tours: Content Meets Culture – Conversations with Experts 

In an effort to maximize educational value, content, and time, the AAOA Education Committee has…

read more

Menu

FDA Revised Draft Insanitary Conditions Guidance

The Food and Drug Administration (FDA) states, in a revised draft guidance released this week, that it does not intend to enforce the “insanitary conditions” provision of the Food, Drug and Cosmetic Act against physicians that compound or mix in their own offices for their own patients. In the 2016 draft guidance, allergists that prepared allergen immunotherapy in their offices would have been subject to the same stringent environmental and engineering controls and sterility testing requirements applicable to compounding facilities that make high risk sterile preparations intended for intravenous, spinal, or other systemic means of administration. It is important to note that this revised guidance is a draft, and the FDA can change its position.

The AAOA, AAAAI, and ACAAI, along with the AMA and others, submitted comments and testimony concerning patient access to care and a lack of evidence of adverse events from sterility problems in physician in-office compounding. We shared with the FDA our concern that patients face a greater risk of anaphylactic reaction to allergen extract mixed outside the watchful control of allergists’ offices.